Blurbs

Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Halozyme (HALO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (AZNResearch Report), Halozyme (HALOResearch Report) and AN2 Therapeutics, Inc. (ANTXResearch Report) with bullish sentiments.

AstraZeneca (AZN)

In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on AstraZeneca, with a price target of $79.00. The company’s shares closed last Friday at $62.77.

According to TipRanks.com, Berens is a 4-star analyst with an average return of 3.9% and a 46.8% success rate. Berens covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Zentalis Pharmaceuticals, and Theseus Pharmaceuticals.

Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of $77.00.

See today’s best-performing stocks on TipRanks >>

Halozyme (HALO)

SVB Securities analyst David Risinger maintained a Buy rating on Halozyme today and set a price target of $62.00. The company’s shares closed last Friday at $53.97, close to its 52-week high of $54.67.

According to TipRanks.com, Risinger is a 4-star analyst with an average return of 12.6% and a 66.0% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.

Currently, the analyst consensus on Halozyme is a Strong Buy with an average price target of $56.00, a 3.0% upside from current levels. In a report issued on November 9, JMP Securities also reiterated a Buy rating on the stock with a $62.00 price target.

AN2 Therapeutics, Inc. (ANTX)

In a report released today, Joseph Schwartz from SVB Securities maintained a Buy rating on AN2 Therapeutics, Inc., with a price target of $25.00. The company’s shares closed last Friday at $14.87.

According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.9% and a 33.2% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Crinetics Pharmaceuticals, and Mereo Biopharma Group Plc.

Currently, the analyst consensus on AN2 Therapeutics, Inc. is a Moderate Buy with an average price target of $25.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AZN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More